Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In vitro and in vivo efficacy of Tecovirimat against a recently emerged 2022 Monkeypox virus isolate
approval coming soon$$$$$$$
https://pubmed.ncbi.nlm.nih.gov/36318038/
CHRISTINA HUTSON, CDC [00:20:10]
Because of these findings, from the start of the outbreak, we have been monitoring the F13L gene within sequenced isolates. At this time, CDC has analyzed sequence data for more than 4,000 specimens from across the United States, of which 11 were found to have genetic changes in the F13L gene during those sequence surveillance efforts.
When tested within the lab, using a cell culture based sensitivity assay, those 11 isolates were sensitive to tecovirimat, showing no evidence of resistance.
We’re currently working on a health advisory related, in part, to development of tecovirimat resistance virus during prolonged tecovirimat treatment. We wanted to let everyone know that this would be coming out soon, and there’ll be more information for providers about the potential for tecovirimat resistance.
-And we hope to have that HAN out by the middle of next week-
https://www.getrevue.co/profile/alexander_tin/issues/notes-for-11-14-2022-1459787
Is Monkeypox still about 95+% sexually transmitted ?
Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations
https://www.nature.com/articles/s41564-022-01269-8
ER is good: Approximately $61 Million of International Sales in the Third Quarter –
As of September 30, 2022, we had $109.7 million in cash and cash equivalents compared with $103.1 million at December 31, 2021.
As of September 30, 2022, we had outstanding purchase orders associated with manufacturing obligations in the aggregate amount of approximately $21.8 million.
https://investor.siga.com/news-releases/news-release-details/siga-reports-financial-results-three-and-nine-months-ended-0
Biden Admin Renews Public Health Emergency Over Monkeypox
https://www.zerohedge.com/medical/biden-admin-renews-public-health-emergency-over-monkeypox
WHO declares monkeypox still a global health emergency
WHO kept monkeypox on its highest alert level
https://www.foxnews.com/health/who-declares-monkeypox-still-global-health-emergency
CDC has altered their view and comments about the effectiveness of TPOXX. Their website, updated on Oct 18, now reads:
"While monkeypox symptoms can resolve on their own, treatment for orthopoxviruses is available and can provide relief and decrease disease severity for persons with monkeypox. The treatment is tecovirimat (TPOXX), available as a pill or intravenous (IV) infusion. At this time, TPOXX is available through state and territorial health departments and CDC."
https://www.cdc.gov/poxvirus/monkeypox/health-departments/intervention-services.html
IN CENTRAL AFRICA, A DEADLY MONKEYPOX VARIANT IS SURGING
https://www.nationalgeographic.co.uk/science-and-technology/2022/10/in-central-africa-a-deadly-monkeypox-variant-is-surging/amp
New York and Nevada report first monkeypox deaths
https://news.yahoo.com/u-monkeypox-deaths-rise-4-184822233.html
Mass General Brigham studying whether antiviral tecovirimat helps treat monkeypox
https://www.bostonherald.com/2022/10/19/mass-general-brigham-studying-whether-antiviral-tecovirimat-helps-treat-monkeypox/
a 2week old infant....."A 2-week course of enteral tecovirimat (at a dose of 50 mg twice a day) was commenced in combination with intravenous cidofovir. After 4 weeks in intensive care, including 14 days of invasive ventilation, the infant recovered and was discharged home."
https://www.nejm.org/doi/full/10.1056/NEJMc2210828
SIGA Provides Update on Progress in Clinical Trials
SIGA disclosed that the Company had received, as of mid September, approximately $76 million of international orders for oral TPOXX from twelve international customers.
https://investor.siga.com/news-releases/news-release-details/siga-provides-update-progress-clinical-trials-assess-use-tpoxx-r
Monkeypox: A dangerous variant circulating in the DRC could go global
https://www.newscientist.com/article/2341569-monkeypox-a-dangerous-variant-circulating-in-the-drc-could-go-global/
$SIGA
Q3 ended last week. At least $80m in sales compared to $9m reported Q2. Nov 4'ish should have the Q3 pr$$$$$$$$
The monkeypox virus is mutating. Are scientists worried
If health officials detect an uptick in the number of virus samples carrying these mutations, that could be a possible signal that they are helping the virus to spread.
The good news is that, although the monkeypox virus continues to evolve, no mutations have affected the part of its genome that encodes a protein targeted by tecovirimat, an antiviral drug being tested for use against monkeypox in humans.
https://www.nature.com/articles/d41586-022-03171-z
Awesome DD you are sharing here, many thanks.
I am close to buying more shares... Looking for the bottom to add..
To score grant R&D money for testing improved versions, just in case?
"and say a mutation may be one amino acid away from rendering this drug totally useless"
NEWS OUT: SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
https://investor.siga.com/news-releases/news-release-details/siga-technologies-announces-new-contract-awarded-us-department
SIGA expects to complete delivery of these most recent orders in 2022. To date this year, including the recent orders, SIGA has received approximately $76 million of international orders for oral TPOXX (tecovirimat) from twelve international customers. It is currently expected that at least $65 million of these orders will be delivered in 2022.
news: SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
September 26, 2022 at 10:07 AM EDT
https://investor.siga.com/news-releases/news-release-details/siga-announces-approximately-16-million-international
Today, the Commission has secured over 10,000 treatment courses of tecovirimat to treat Monkeypox.
https://ec.europa.eu/commission/presscorner/detail/en/ip_22_5482
SIGA Technologies has now secured the rights to sell TPOXX to commercial customers and is working to make this life-saving medication more widely available
https://stock.vi.app/market-price/siga-technologies-to-sell-tpoxx-to-commercial-customers/
winners$$$$$$$$$$$
Vanderbilt researchers are developing an artificial intelligence algorithm that can precisely track and count monkeypox lesions. They are also spearheading the effort to develop lesion classification guidelines, which will be used when evaluating the potential use of tecovirimat, an antiviral that is FDA-approved against smallpox, as a therapy for monkeypox.
https://news.vanderbilt.edu/2022/09/15/vanderbilt-nih-and-the-institut-national-de-recherche-biomedicale-team-up-to-tackle-monkeypox%e2%80%af/
Go to 38:06......listen to his answer about eligibility and indication for TPOXX and you tell me- do you hear anything that indicates they were worried about drug resistance? NO
https://www.ama-assn.org/about/events/what-physicians-need-know-about-tecovirimat-tpoxx-treatment-monkeypox
Interview is a Stark contrast to the CDC website guidance they posted today.
WHY would they literally massively promote this drug at a webinar one day and then, literally OUT of nowhere, the next day, LIE and say a mutation may be one amino acid away from rendering this drug totally useless
"We do expect it to be available soon Tecovirimat. And CDC is currently developing an expanded access IND protocol to help facilitate the use of this product as a treatment for monkeypox as well," the CDC's Brett Petersen told doctors at the AMA webinar.
According to federal data, nearly 2,000 patients diagnosed with monkeypox have been treated with TPOXX so far, nearly all of them men. Only 24 women have been confirmed to have received TPOXX to treat monkeypox infections.
Ten of the patients in the study reported a complete resolution of their monkeypox lesions one week after starting treatment. The majority of the patients took TPOXX for 14 days. However, the study did not include a control group, limiting the researchers’ ability to measure effectiveness.
it's written on the wall........approved
winner$$$$$$$$
Do you have the news link?
Keep the $SIGA MonkeyPox updates coming, I am sharing them as I have time
Update 09/14:
Dr. Fauci confirmed that TPOXX is currently undergoing phase-3 trials imminently. It’s just a matter of time until we get the approval by the FDA and then others will follow.
$SIGA It’s a great time to scoop up bargain stocks$$$$$$$$$$$$$$$$
Best Life: Using antivirals to treat monkeypox
“T-POXX is a medication [that] stops the replication, stops a duplication of the virus in your body. So, it’s very effective – if you can get one,” said
Winter.
https://www.actionnews5.com/2022/09/14/best-life-using-antivirals-treat-monkeypox/
Two Cases of Monkeypox-Associated Encephalomyelitis — Colorado and the District of Columbia, July–August 2022
Early Release / September 13, 2022
https://www.cdc.gov/mmwr/volumes/71/wr/mm7138e1.htm?s_cid=mm7138e1_w
Il CDC registra 646 nuovi casi di vaiolo delle scimmie negli Stati Uniti nelle ultime 24 ore mentre il conteggio dei casi sale a 22.630.
Spain : +103 (6,947)
France : +48 (3,833)
Belgium +18 (744)
France has an alarmingly high new female cases as they accounted for 12.9% of all new cases in the prior week.
Mexico records a big jump in monkeypox cases this week after the administration recorded 263 new cases for a total case count of 1,051.
This week we increased cases by about 33% compared to 55% last week.
$SIGA
Why the number of monkey pox infections has not been updated since September 9?
This will be one of the strongest reasons for the FDA to approve TPOXX ASAP: Pregnant women infected by monkeypox have a 77% chance of fetal demise.
https://pubmed.ncbi.nlm.nih.gov/36096413/
First US death due to monkeypox confirmed in Los Angeles County
https://edition.cnn.com/2022/09/12/health/california-monkeypox-death/index.html
don't forget to register! Webinar this Tuesday at 11 am focused on TPOXX! FDA, CDC and AMA!
https://www.ama-assn.org/about/events/what-physicians-need-know-about-tecovirimat-tpoxx-treatment-monkeypox
good for us$$$$$$$$$$$
looks good for next week, it's definitely safe and there's PLENTY of evidence to show it's effective. None to show it isn't that I'm aware of...and besides- risk is nothing in comparison to benefit. TPOXX currently qualifies and meets ALL OF THE FDA CRITERIA for EUA!
Nice wabbit Hop back up and green today. $SIGA
It’s the PoochPox !
https://m.thefly.com/new-landing/3579126
Siga's Tpoxx generally well tolerated as monkeypox treatment, CDC says
Monkeypox Has Potential to Cause Heart Problems
Patient in case study developed myocarditis following monkeypox infection
https://www.acc.org/About-ACC/Press-Releases/2022/09/01/15/31/Monkeypox-Has-Potential-to-Cause-Heart-Problems
$SIGA
news: U.S. Clinical Trial Evaluating Antiviral for Monkeypox Begins
NIH Trial Gathering Data on Tecovirimat (TPOXX)
September 9, 2022
https://www.niaid.nih.gov/news-events/us-clinical-trial-evaluating-antiviral-monkeypox-begins
Followers
|
49
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1361
|
Created
|
09/25/06
|
Type
|
Free
|
Moderators |
SIGA Technologies, Inc. (Nasdaq: SIGA) is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |